Drug-related Myopathies of Which the Clinician Should Be Aware
Tóm tắt
Từ khóa
Tài liệu tham khảo
Jacobson TA: Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687–700.
• Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858–868. This is a nice comprehensive overview of statin myopathy to date.
• MRC/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, et al.: Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6. This is one of the most comprehensive long-term, placebo-controlled trials undertaken to assess muscle and liver toxicity in patients at high risk for cardiovascular events.
Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C–76C.
Mosshammer D, Lorenz G, Meznaric S, et al.: Statin use and its association with musculoskeletal symptoms—a cross-sectional study in primary care settings. Fam Pract 2009, 26:88–95.
Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97:44C–51C.
Davidson MH, Clark JA, Glass LM, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97:32C–43C.
•• SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al.: SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008, 359:789–799. This was a well-designed study with robust data for proof of principle of genetic susceptibility as a potential cause of statin myopathy.
• Voora D, Shah SH, Spasojevic I, et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609–1616. A sister study to that by the SEARCH Collaborative Group [13••], this study eloquently expanded previous SNP association findings to suggest not only bona fide statin myopathy, but also that patients with myalgias with normal CK can also have a genetic predisposition that may be statin specific rather than a class effect.
Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024–1028.
Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414.
Supala-Berger A, Fine E, Heffner R, Young-McLain E: Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009, 40:657–661.
Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.
Mohaupt MG, Karas RH, Babiychuk EB, et al.: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11–E18.
Wu AH, Smith A, Wians F: Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta 2009, 399:109–111.
• Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341–346. This alternative dosing strategy offers an alternative dosing schedule for statin-intolerant patients.
• Ruisinger JF, Backes JM, Gibson CA, Moriarty PM: Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009, 103:393–394. Like that by Backes et al. [21•], this study provided some data to suggest tolerability and efficacy for alternative statin dosing scheduled in statin-intolerant patients. This study noted a 17% reduction in total cholesterol, a 23% reduction in low-density lipoprotein cholesterol, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all P < 0.001) during a mean follow-up of 4 ± 2 months.
Glueck CJ, Rawal B, Khan NA, et al.: Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009, 58:233–238.
ACCORD Study Group; Buse JB, Bigger JT, Byington RP, et al.: Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i–33i.
Rowan C, Brinker AD, Nourjah P, et al.: Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009, 18:301–309.
• Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185–190. This study demonstrated a robust association between a presumed necrotizing myopathy and statin exposure.
• Christopher-Stine L, Casciola-Rosen L, Hong G, et al.: A novel autoantibody recognizing 200 and100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010 (in press). This study, along with that by Grable-Esposito et al. [28•], shows that patients with statin exposure may go on to develop an immune-mediated myopathy—often a necrotizing myopathy.
Blanco-Colio LM, Villa A, Ortego M, et al.: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17–26.
Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830–839, W147–W149.
Lapi F, Gallo E, Bernasconi S, et al.: Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian surveillance system of natural health products. Br J Clin Pharmacol 2008, 66:572–574.
Halbert SC, French B, Gordon RY, et al.: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198–204.
Florentin M, Liberopoulos EN, Elisaf MS: Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008, 62:88–96.
Dalakas MC, Illa I, Pezeshkpour GH, et al.: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098–1105.
Pfeffer G, Côté HC, Montaner JS, et al.: Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009, 73:71–72.
Somani AK, Swick AR, Cooper KD, McCormick TS: Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341–1349.
Seok JI, Lee DK, Lee CH, et al.: Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49:2080–2086.
Casado E, Gratacós J, Tolosa C, et al.: Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65:385–390.
Kalajian AH, Callen JP: Myopathy induced by antimalarial agents: the relevance of screening muscle enzyme levels. Arch Dermatol 2009, 145:597–600.
Covar RA, Leung DY, McCormick D, et al.: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106:651–659.
Bowyer SL, LaMothe MP, Hollister JR: Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985, 76:234–242.
• Dirks-Naylor AJ, Griffiths CL: Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009, 117:1–7. This is an intriguing and novel concept to help elucidate the mechanism of glucocorticoid-related myopathy.
Ochi S, Taniguchi K, Nagashima M: Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009, 19:443–446.
Hinojosa J, Borrás-Blasco J, Maroto N, et al.: Severe myalgia associated with adalimumab treatment in a patient with Crohn’s disease. Ann Pharmacother 2008, 42:1130–1133.